Abstract
Lamotrigine is a novel anticonvulsant, which has proven to be effective both as add-on and monotherapy. 13 studies have demonstrated efficacy in 1096 children with a variety of seizure types. Tolerability information in these studies was collected in a standard fashion, where investigators reported all adverse events regardless of the perceived relationship to the test therapies. Generally, lamotrigine treatment in these clinical trials was generally given at higher initial doses and faster dose escalations than are currently recommended.
Most adverse events associated with lamotrigine were mild to moderate in severity and did not result in discontinuation of treatment. Results from placebo-controlled, add-on trials showed that 85% of lamotrigine recipients experienced an adverse event compared with 83% of placebo recipients. Lamotrigine was associated with an increased risk of adverse events in the nervous system (dizziness, tremor, ataxia, and diplopia), gastrointestinal tract (nausea), and urinary tract (infection). The incidence of most adverse events was lower among lamotrigine recipients in monotherapy trials than in add-on trials, suggesting that concurrent anticonvulsant treatment or drug interactions can be confounding risk factors above that of lamotrigine treatment alone. Skin rash associated with hospitalisation and the discontinuation of study drug was reported more frequently by lamotrigine recipients than by placebo recipients and more frequently by children than by adults. The simultaneous use of valproic acid (sodium valproate) was associated with an increased incidence of rash.
Lamotrigine, an effective broad spectrum anticonvulsant, is well tolerated in children. The qualitative features of adverse events that occur with lamotrigine treatment are similar for children and adults. The incidence of rash may be reduced with proper initial dosing and dose escalation.
Similar content being viewed by others
References
Leach MJ, Lees G, Riddall DR. Lamotrigine: mechanisms of action. In: Levy RH, Mattson RH, Meldrum BS, et al., editors. Antiepileptic Drugs. 4th ed. New York (NY): Raven Press, 1995: 861–9
Xie X, Lancaster B, Peakman T, et al. Interaction of the antiepileptic drug lamotrigine with recombinant rat brain type IIa Na+ and with native Na+ channels in rat hippocampal neurones. Pflugers Arch 1995; 430: 437–46
Goa KL, Ross SR, Chrisp P. Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1993; 46: 152–76
Xie X, Hagan RM. Cellular and molecular actions of lamotrigine: possible mechanisms of efficacy in bipolar disorder. Neuropsychobiology 1998; 38: 119–30
Frank LM, Enlow T, Holmes GL, et al. Lamictal® (lamotrigine) monotherapy for Typical Absence Seizures in children. Epilepsia 1999; 40: 973–9
Hosford DA, Wang Y. Utility of the lethargic (lh/lh) mouse model of absence seizures in predicting the effects of lamotrigine, vigabatrin, tiagabine, gabapentin, and topiramate against human absence seizures. Epilepsia 1997; 38: 408–14
Hauser WA. The prevalence and incidence of convulsive disorders in children. Epilepsia 1994; 35Suppl 2: 51–6
Gilliam F, Vazquez B, Sackellares JC, et al. An active-control trial of lamotrigine monotherapy for partial seizures. Neurology 1998; 51: 1018–25
Krejcova H, Salemanova Z, Tmavska Z, et al. The efficacy and long-term tolerability of lamotrigine in treatment-resistant epilepsy [abstract]. J Neurol 1990; 237Suppl 1: S32
Binnie CD, Debets RMC, Engelsman M, et al. Double-blind crossover trial of lamotrigine (Lamictal®) as add-on therapy in intractable epilepsy. Epilepsy Res 1989; 4: 222–9
Schapel GJ, Beran RG, Vajda FJE, et al. Double-blind, placebo-controlled crossover study of lamotrigine in treatment-resistant partial seizures. J Neurol Neurosurg Psychiatry 1993; 56: 448–53
Brodie MJ, Richens A, Yuen AWC. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995; 345: 476–9
Steiner TJ, Dellaportas CI, Findley LJ, et al. Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin. Epilepsia 1999; 40: 601–7
Uvebrant P, Bauzienne R. Intractable epilepsy in children. Neuropediatrics 1994; 25: 284–9
Duchowny M, Pellock JM, Graf WD, et al. A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children. Neurology 1999; 53: 1724–31
Motte J, Trevathan E, Arvidsson JFV, et al. Lamotrigine for the generalized seizures associated with the Lennox-Gastaut syndrome. N Engl J Med 1997; 337: 1807–12
Lamotrigine (Lamictal®) Product Information. Glaxo Wellcome, Research Triangle Park, (NC), 1998
Messenheimer JA. Rash in adult and pediatric patients treated with lamotrigine. Can J Neurol Sci 1998; 25Suppl 4: 514–8.
Messenheimer J, Mullens EL, Giorgi L, et al. Safety review of adult clinical trial experience with lamotrigine. Drug Saf 1998; 18(4): 281–96
Schachter SC, Leppik IE, Matsuo F, et al. Lamotrigine: a six-month, placebo-controlled safety and tolerance study. J Epilepsy 1995; 8: 201–9
Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981; 22: 489–501
Wallace SJ. A comparative review of the adverse effects of anticonvulsants in children with epilepsy. Drug Saf 1996; 15: 378–93
Troupin AS. Dose-related adverse effects of anticonvulsants. Drug Saf 1996; 14: 299–328
Phenytoin (Dilantin®) Product Information. Morris Plains (NJ): Parke-Davis, 1996
Carbamazepine (Tegretol®) Product Information. East Hanover (NJ): Novartis Pharmaceuticals, 1997
Divalproex sodium (Depakote®) Product Information. North Chicago (IL): Abbott Laboratories, 1997
Tennis P, Stern RS. Risk of serious cutaneous disorders after the initiation of use of phenytoin, carbamazepine or sodium valproate: a record linkage study. Neurology 1997; 49: 542–9
Roujeau JC, Stern RS. Severe adverse cutaneous reaction to drugs. N Engl J Med 1994; 331: 1272–85
Chan HL, Stern RS, Arndt KA, et al. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among out-patients. Arch Dermatol 1990; 126: 43–7
Delattre JY, Safai B, Posner JB. Erythema multiforme and Stevens-Johnson syndrome in patients receiving cranial irradiation and phenytoin. Neurology 1988; 38: 194–8
Rzany B, Correia O, Kelly JP, et al for the Study Group of the International Case-Control Study on Severe Cutaneous Adverse Reactions. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Lancet 1999; 353: 2190–4
Anderson GD, Yau MK, Gidal BE, et al. Bidirectional interaction of valproate and lamotrigine in healthy subjects. Clin Pharmacol Ther 1996; 60: 145–56
May TW, Rambeck B, Jurgens U. Serum concentrations of lamotrigine in epileptic patients: The influence of dose and comedication. Ther Drug Monit 1996; 18: 523–31
Yuen AWC, Land G, Weatherly BC, et al. Sodium valproate acutely inhibits lamotrigine metabolism. Br J Clin Pharmacol 1992; 33: 511–3
Chen C, Rudd D, Messenheimer, et al. Pediatric dosing recommendations of lamotrigine based on a population pharmacokinetic model [abstract]. Epilepsia 1999; 40Suppl. 7: 113
Acknowledgements
We thank all the investigators, study site coordinators, and clinical research scientists who took part in the lamotrigine clinical studies and assiduously reported adverse events. GlaxoWellcome Inc. supported the costs of this database. We thank Gilda Womble MS, biostatistician at GlaxoWellcome, for data summary and analysis and Anthony W. Fox MD, PhD, FFPM (EBD Group Inc., Carlsbad, CA) and Elizabeth Field, PhD (GlaxoWellcome) for writing and editing assistance.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Messenheimer, J.A., Giorgi, L. & Risner, M.E. The Tolerability of Lamotrigine in Children. Drug-Safety 22, 303–312 (2000). https://doi.org/10.2165/00002018-200022040-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-200022040-00003